References
- World Health Organization. Global Health Observatory 2012. Available at: http://www.who.int/gho/mortality_burden_disease/en/ [Last accessed 8 September 2014]
- American Heart Association. Cardiovascular disease and diabetes. Available at: http://www.heart.org/HEARTORG/Conditions/Diabetes/WhyDiabetesMatters/Cardiovascular-Disease-Diabetes_UCM_313865_Article.jsp [Last accessed 8 September 2014]
- de Vries FM, Denig P, Pouwels KB, et al. Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis. Drugs 2012;72:2365-73
- de Vries FM, Kolthof J, Postma MJ, et al. Efficacy of standard and intensive statin treatment for the secondary prevention of cardiovascular and cerebrovascular events in diabetes patients: a meta-analysis. PLoS One 2014: doi: 10.1371/journal.pone.011124. Published online: 5 November 2014
- Simpson RJ, Mendys P. The effects of adherence and persistence on clinical outcomes in patients treated with statins: a systematic review. J Clin Lipidol 2010;4:462-71
- Chodick G, Shalev V, Gerber Y, et al. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther 2008;30:2167-79
- Latry P, Molimard M, Dedieu B, et al. Adherence with statins in a real-life setting is better when associated cardiovascular risk factors increase: a cohort study. BMC Cardiovasc Disord 2011;11:46
- Benner JS, Glynn RJ, Mogun H, et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002;288:455-61
- Donnelly LA, Doney AS, Morris AD, et al. Long-term adherence to statin treatment in diabetes. Diabet Med 2008;25:850-5
- European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, et al; ESC Committee for Practice Guidelines (CPG) 2008–2010, 2010–2012 Committees. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818
- Practice guideline cardiovascular risk management from the Dutch General Practitioners Society (Tweede herziening). [In Dutch, NHG-standaard Cardiovasculair risicomanagement.] Huisarts Wet 2012;55:14-28
- Poluzzi E, Piccinni C, Carta P, et al. Cardiovascular events in statin recipients: impact of adherence to treatment in a 3-year record linkage study. Eur J Clin Pharmacol 2011;67:407-14
- Monster TB, Janssen WM, de Jong PE, et al. PREVEND Study Group Prevention of REnal and Vascular ENT Stage Disease. Pharmacy data in epidemiological studies: an easy to obtain and reliable tool. Pharmacoepidemiol Drug Saf 2002;11:379-84
- Vegter S, de Jong-van den Berg LT. Misdiagnosis and mistreatment of a common side-effect – angiotensin-converting enzyme inhibitor-induced cough. Br J Clin Pharmacol 2010;69:200-3
- Vegter S, Nguyen NH, Visser ST, et al. Compliance, persistence, and switching patterns for ACE inhibitors and ARBs. Am J Manag Care 2011;17:609-16
- ATC codes. Available at: http://www.whocc.no/atc_ddd_index/ [Last accessed 8 September 2014]
- Leufkens HG, Urquhart J. Automated pharmacy record linkage in the Netherlands. In: Anonymous (eds) Pharmacoepidemiology. New York: Wiley, 2006:311–22
- de Vries FM, Denig P, Visser ST, et al. Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands. Value Health 2014;17:223-30
- Voorham J, Haaijer-Ruskamp FM, van der Meer K, et al. Quality of the treatment of type 2 diabetes: results from the GIANTT project 2004–2007. Ned Tijdschr Geneeskd 2010;154:A775
- Levesque LE, Hanley JA, Kezouh A, et al. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 2010;340:b5087
- Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3-12
- Daskalopoulou SS, Delaney JA, Filion KB, et al. Discontinuation of statin therapy following an acute myocardial infarction: a population-based study. Eur Heart J 2008;29:2083-91
- Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-34
- Abraha I, Montedori A, Stracci F, et al. Statin compliance in the Umbrian population. Eur J Clin Pharmacol 2003;59:659-61